Home > Insider Trading > Filing (0001192621-15-000002)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
820081	Cambrex Corp	CBM	Pharmaceutical Preparations (2834)	222476135

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1192621	M Steven Klosk	One Meadowlands Plaza East Rutherford NJ 07073	President And Ceo	Yes	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2015-11-05	49,121	$0.00	149,991	No	4	M	Direct
Common Stock	Disposition	2015-11-05	38,321	$50.57	111,670	No	4	S	Direct
Common Stock	Disposition	2015-11-05	10,800	$51.31	100,870	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Phantom Stock Units	Disposition	2015-11-05	49,121	$0.00	49,121	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0	2015-11-05	2015-11-05	No	4	M	Direct

Footnotes

Phantom stock units held by reporting person were issued pursuant to the Deferred Compensation Plan of Cambrex Corporation (as Amended and Restated as of March 1, 2001). Each phantom stock unit was the economic equivalent of one share of Cambrex common stock. On November 5, 2015, all of the reporting person's phantom stock units were settled for cash.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.11 to $51.09 inclusive. The reporting person untertakes to provide to Cambrex Corporation, any security holder of Cambrex Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Footnote 2 to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.10 to $51.525 inclusive. The reporting person untertakes to provide to Cambrex Corporation, any security holder of Cambrex Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Footnote 3 to this Form 4.